Caris Life Sciences Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 1, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Market Cap	4,687	7,623	-	-	-
Enterprise Value	4,214	7,201	0	0	0
Last Close Price	16.58	26.98	-	-	-
PS Ratio	5.08	9.39	-	-	-
PB Ratio	7.96	2.44	-	-	-
P/TBV Ratio	1.24	1.44	-	-	-
P/FCF Ratio	37.31	113.95	-	-	-
P/OCF Ratio	31.26	91.67	-	-	-
EV/Sales Ratio	4.64	8.87	-	-	-
EV/EBITDA Ratio	32.67	106.33	-	-	-
EV/EBIT Ratio	38.89	159.63	-	-	-
EV/FCF Ratio	34.13	107.65	-	-	-
Debt / Equity Ratio	0.12	0.12	-1.15	-8.46	0.67
Debt / EBITDA Ratio	2.96	5.60	-	-	-
Debt / FCF Ratio	3.09	5.67	-	-	-
Net Debt / Equity Ratio	-0.14	-0.13	-0.12	-0.02	0.11
Net Debt / EBITDA Ratio	-3.43	-6.22	-1.50	-0.15	0.72
Net Debt / FCF Ratio	-3.58	-6.29	-1.23	-0.14	0.58
Asset Turnover	0.79	1.11	1.09	0.54	0.36
Inventory Turnover	4.06	5.29	5.27	4.52	3.80
Quick Ratio	6.35	7.17	0.94	1.90	3.31
Current Ratio	7.05	7.85	1.30	2.55	3.77
Return on Equity (ROE)	-2.31%	-4.78%	189.92%	-293.83%	-127.28%
Return on Assets (ROA)	9.43%	6.14%	-67.96%	-56.54%	-44.01%
Return on Invested Capital (ROIC)	54.81%	24.43%	-141.47%	-154.94%	-143.70%
Return on Capital Employed (ROCE)	10.74%	7.67%	-103.66%	-71.15%	-54.39%
FCF Yield	2.68%	0.88%	-	-	-
Buyback Yield / Dilution	-543.56%	-371.05%	-1.59%	-104626.10%	-
Total Shareholder Return	-543.56%	-371.05%	-1.59%	-104626.10%	-

SEC Filings: 10-K · 10-Q